Bone Mineral Density Quantitative Trait Locus 15 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

BMND15 MCID: BNM029 MIFTS: 49	Bone Mineral Density Quantitative Trait Locus 15 (BMND15) Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Bone Mineral Density Quantitative Trait Locus 15

MalaCards integrated aliases for Bone Mineral Density Quantitative Trait Locus 15:

Name: Bone Mineral Density Quantitative Trait Locus 15 ⁵⁷ ⁵ ³⁸

Osteoporosis ⁵⁷ ⁷¹

Metaphyseal Fracture, Susceptibility to ⁵⁷

Compression Fracture, Susceptibility to ⁵⁷

Osteoporosis, Susceptibility to ⁵⁷

Fractures, Compression ⁷¹

Metaphyseal Fractures ⁵

Metaphyseal Fracture ⁵⁷

Compression Fracture ⁵⁷

Bmnd15 ⁵⁷

Characteristics:

Inheritance:

Autosomal dominant ⁵⁷

Classifications:

MalaCards categories:
Global: Genetic diseases Fetal diseases Rare diseases
Anatomical: Bone diseases

See all MalaCards categories (disease lists)

External Ids:

OMIM® ⁵⁷ 613418

MedGen ⁴⁰ C3150680

SNOMED-CT via HPO ⁶⁹ 64859006

UMLS ⁷¹ C0029456 C0521169

Sources

Summaries for Bone Mineral Density Quantitative Trait Locus 15

MalaCards based summary: Bone Mineral Density Quantitative Trait Locus 15, also known as osteoporosis, is related to osteoporosis and bone mineral density quantitative trait locus 8, and has symptoms including tremor, back pain and angina pectoris. An important gene associated with Bone Mineral Density Quantitative Trait Locus 15 is MIR2861 (MicroRNA 2861). The drugs Calcium carbonate and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and spinal cord, and related phenotype is osteoporosis.

More information from OMIM: 613418

Sources

Related Diseases for Bone Mineral Density Quantitative Trait Locus 15

Diseases in the Bone Mineral Density Quantitative Trait Locus 15 family:

Bone Mineral Density Quantitative Trait Locus 4	Bone Mineral Density Quantitative Trait Locus 18
Bone Mineral Density Quantitative Trait Locus 1	Bone Mineral Density Quantitative Trait Locus 2
Bone Mineral Density Quantitative Trait Locus 3	Bone Mineral Density Quantitative Trait Locus 5
Bone Mineral Density Quantitative Trait Locus 6	Bone Mineral Density Quantitative Trait Locus 7
Bone Mineral Density Quantitative Trait Locus 8	Bone Mineral Density Quantitative Trait Locus 9
Bone Mineral Density Quantitative Trait Locus 10	Bone Mineral Density Quantitative Trait Locus 11
Bone Mineral Density Quantitative Trait Locus 12	Bone Mineral Density Quantitative Trait Locus 13
Bone Mineral Density Quantitative Trait Locus 14	Bone Mineral Density Quantitative Trait Locus 16
Bone Mineral Density Quantitative Trait Locus 17

Diseases related to Bone Mineral Density Quantitative Trait Locus 15 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1402)

#	Related Disease	Score	Top Affiliating Genes
1	osteoporosis	31.9	PDLIM4 MIR2861 CALCR
2	bone mineral density quantitative trait locus 8	11.9
3	osteoporosis, juvenile	11.8
4	osteoporosis-pseudoglioma syndrome	11.8
5	glucocorticoid-induced osteoporosis	11.6
6	hajdu-cheney syndrome	11.6
7	nephrolithiasis/osteoporosis, hypophosphatemic, 1	11.5
8	nephrolithiasis/osteoporosis, hypophosphatemic, 2	11.5
9	juvenile primary osteoporosis	11.5
10	bone mineral density quantitative trait locus 18	11.5
11	bone mineral density quantitative trait locus 16	11.4
12	osteoporosis and oculocutaneous hypopigmentation syndrome	11.3
13	osteoporosis, childhood- or juvenile-onset, with developmental delay	11.3
14	bone disease	11.3
15	rickets	11.3
16	premature menopause	11.2
17	dominant hypophosphatemia with nephrolithiasis or osteoporosis	11.1
18	osteoporosis-macrocephaly-blindness-joint hyperlaxity syndrome	11.1
19	hypophosphatemic nephrolithiasis/osteoporosis	11.1
20	nestor-guillermo progeria syndrome	11.1
21	werner syndrome	11.1
22	syndromic x-linked intellectual disability snyder type	11.1
23	geroderma osteodysplasticum	11.1
24	hyperparathyroidism	11.1
25	multicentric osteolysis, nodulosis, and arthropathy	11.1
26	prader-willi habitus, osteopenia, and camptodactyly	11.1
27	winchester syndrome	11.1
28	ehlers-danlos syndrome, classic-like, 2	11.1
29	lrp5-related primary osteoporosis	11.1
30	macroepiphyseal dysplasia with osteoporosis, wrinkled skin, and aged appearance	11.1
31	lysinuric protein intolerance	11.0
32	amino aciduria with mental deficiency, dwarfism, muscular dystrophy, osteoporosis, and acidosis	11.0
33	intellectual developmental disorder, x-linked, syndromic, snyder-robinson type	11.0
34	aromatase deficiency	11.0
35	epiphyseal dysplasia, multiple, with early-onset diabetes mellitus	11.0
36	mucolipidosis iii alpha/beta	11.0
37	conn's syndrome	11.0
38	hyperthyroidism	11.0
39	celiac disease 1	11.0
40	cholangitis, primary sclerosing	11.0
41	cerebrotendinous xanthomatosis	11.0
42	turner syndrome	11.0
43	bone mineral density quantitative trait locus 3	10.9
44	spondyloocular syndrome	10.9
45	cleidocranial dysplasia 1	10.9
46	hyperparathyroidism 1	10.9
47	dyskeratosis congenita, autosomal recessive 1	10.9
48	ehlers-danlos syndrome, kyphoscoliotic type, 1	10.9
49	hyaline fibromatosis syndrome	10.9
50	lichtenstein syndrome	10.9

Graphical network of the top 20 diseases related to Bone Mineral Density Quantitative Trait Locus 15:

Sources

Symptoms & Phenotypes for Bone Mineral Density Quantitative Trait Locus 15

Human phenotypes related to Bone Mineral Density Quantitative Trait Locus 15:

³⁰

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	osteoporosis ³⁰			HP:0000939

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Skeletal:
osteoporosis
compression fractures (in homozygotes)
metaphyseal fractures (in homozygotes)

Clinical features from OMIM®:

613418 (Updated 08-Dec-2022)

UMLS symptoms related to Bone Mineral Density Quantitative Trait Locus 15:

tremor; back pain; angina pectoris; sciatica; equilibration disorder; muscle cramp; pelvic pain

Sources

Drugs & Therapeutics for Bone Mineral Density Quantitative Trait Locus 15

Drugs for Bone Mineral Density Quantitative Trait Locus 15 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 387)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Calcium carbonate

Approved, Investigational

Phase 4

471-34-1

Pioglitazone

Approved, Investigational

Phase 4

111025-46-8

4829

Hydrocortisone succinate

Approved

Phase 4

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 4

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 4

50-23-7

3640 5754

Clobetasol

Approved, Experimental, Investigational

Phase 4

25122-46-7, 25122-41-2

2791 5311051 32798

Linagliptin

Approved

Phase 4

668270-12-0

57389748 10096344

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Tetracycline

Approved, Vet_approved, Withdrawn

Phase 4

60-54-8

5353990

Bazedoxifene

Approved, Investigational

Phase 4

198481-32-2

154257

Medroxyprogesterone acetate

Approved, Investigational

Phase 4

520-85-4, 71-58-9

6279 10631

Estradiol

Approved, Investigational, Vet_approved

Phase 4

50-28-2

5757

Polyestradiol phosphate

Approved

Phase 4

28014-46-2

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

23431961

Potassium citrate

Approved, Investigational, Vet_approved

Phase 4

866-84-2

Strontium ranelate

Approved, Withdrawn

Phase 4

135459-87-9

Pamidronic acid

Approved

Phase 4

40391-99-9

4674

Demeclocycline

Approved

Phase 4

127-33-3

5311063

Racepinephrine

Approved, Vet_approved

Phase 4

51-43-4, 329-65-7

838 5816

Lactitol

Approved, Investigational

Phase 4

585-86-4

157355

Tibolone

Approved, Investigational

Phase 4

5630-53-5

5470 444008

Valsartan

Approved, Investigational

Phase 4

137862-53-4

60846

Angiotensin II

Approved, Investigational

Phase 4

68521-88-0, 11128-99-7, 4474-91-3

172198

Esomeprazole

Approved, Investigational, Vet_approved

Phase 4

73590-58-6, 119141-88-7

9568614 4594

Atorvastatin

Approved

Phase 4

134523-00-5

60823

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Progesterone

Approved, Vet_approved

Phase 4

57-83-0

5994

Vildagliptin

Approved, Investigational

Phase 4

274901-16-5

6918537

Gliclazide

Approved

Phase 4

21187-98-4

3475

Liraglutide

Approved

Phase 4

204656-20-2

44147092 16134956

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Abaloparatide

Approved, Investigational

Phase 4

247062-33-5

Zoledronic acid

Approved

Phase 4

118072-93-8

68740

Cinacalcet

Approved

Phase 4

226256-56-0

156419

Lamivudine

Approved, Investigational

Phase 4

134678-17-4

60825

Dolutegravir

Approved

Phase 4

1051375-16-6

57414794 54726191

Racivir

Approved, Investigational

Phase 4

143491-57-0, 143491-54-7

60877

Pravastatin

Approved

Phase 4

81093-37-0

54687

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Ibuprofen

Approved

Phase 4

15687-27-1

3672

Acetaminophen

Approved

Phase 4

103-90-2

1983

Acetylsalicylic acid

Approved, Vet_approved

Phase 4

50-78-2

2244

Naproxen

Approved, Vet_approved

Phase 4

22204-53-1

156391 1302

Alendronic acid

Approved

Phase 4

121268-17-5, 66376-36-1

2088

Denosumab

Approved

Phase 4

615258-40-7

Raloxifene

Approved, Investigational

Phase 4

82640-04-8, 84449-90-1

5035

Alfacalcidol

Approved, Nutraceutical

Phase 4

41294-56-8

5282181

Calcitriol

Approved, Nutraceutical

Phase 4

32222-06-3

5280453

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Interventional clinical trials:

(show top 50) (show all 1461)

#	Name	Status	NCT ID	Phase	Drugs
1	Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo	Unknown status	NCT01945788	Phase 4	Teriparatide (rDNA origin)
2	Effect of Mechanical Loading With PTH on Cortical Bone	Unknown status	NCT03232476	Phase 4
3	Generic Zoledronic Acid Versus Original Zoledronic Acid: A Multicenter, Randomized, Open, Paralled-controlled Clinical Postmenopausal Osteoporotic Women Efficacy and Safety Research.	Unknown status	NCT03158246	Phase 4	Generic Zoledronic Acid;Original Zoledronic Acid
4	Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis	Unknown status	NCT00727493	Phase 4	alendronate once weekly 70mg;placebo
5	The Assessment of Osteoporosis Treatment in Post-menopausal Women	Unknown status	NCT03006003	Phase 4	Raloxifene;Alendronate
6	The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab	Unknown status	NCT02130973	Phase 4	Standard Clinical Practice Regimen;Experimental Cyclic Regimen
7	The Efficacy of Denosumab to Reduce Osteoporosis After Spinal Cord Injury	Unknown status	NCT01983475	Phase 4	Denosumab;Placebo (identical Denosumab volume of normal saline)
8	Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis	Unknown status	NCT02389179	Phase 4	Vitamin D3
9	Effects of Omega-3 Fatty Acids on Bone and Frailty	Unknown status	NCT00634686	Phase 4
10	Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid	Unknown status	NCT03926377	Phase 4
11	Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers	Unknown status	NCT02587975	Phase 4	Evogliptin
12	Multi-centre Clinical Trial on Hormone Replacement Treatment in China	Unknown status	NCT01698164	Phase 4	estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
13	A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers	Unknown status	NCT02429232	Phase 4	Pioglitazone;Linagliptin
14	Pilot Study: Does Preventive Adjacent Level Cement Augmentation Positively Affect Reoperation Rates After Osteoporotic Vertebral Compression Fractures?	Unknown status	NCT02489825	Phase 4
15	Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients	Unknown status	NCT02156960	Phase 4	Denosumab treatment in osteoporotic patients;Teriparatide treatment in osteoporotic patients;Denosumab and teriparatide treatment in osteoporotic patients
16	A Randomized, Double-blind, Placebo-controlled Study Evaluating the Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures	Unknown status	NCT01482858	Phase 4
17	Comparisons of the Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels	Unknown status	NCT01765010	Phase 4	Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
18	A Multi Centre, Randomised, Open Label, Cross-over Study to Evaluate the Percentage of False Negative Osteoporosis Diagnosis's Using the Standard Case-finding Procedure as Described by the Dutch Institute for Healthcare (CBO) and to Determine the Preference of Adult Osteoporosis Patients Between Once Monthly Dosing of Ibandronate (150 mg) and Once Weekly Dosing of Alendronate (70 mg)	Completed	NCT00327990	Phase 4	Ibandronate;Alendronate
19	A Prospective Open-Label, Multicenter Study to Evaluate the Change in Bone Turnover Markers After Once Monthly Oral Ibandronate Therapy in Treatment Naive Postmenopausal Osteoporosis Patients	Completed	NCT02598934	Phase 4	Ibandronate
20	Randomized, Open-label, Multi-center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once Monthly Ibandronate and Once Weekly Risedronate. A Six Month, Two-sequence and Two-period Crossover Study.	Completed	NCT00377234	Phase 4	Risedronate;ibandronate [Bonviva/Boniva]
21	The Effects of Teriparatide on Bone Microarchitecture as Determined by High Resolution Magnetic Resonance Imaging and Digital Topological Analysis	Completed	NCT00557310	Phase 4	teriparatide
22	A Randomized, Open-label Study to Investigate the Impact of Bone Marker Feedback on Persistence to Once Monthly Oral Bonviva (Ibandronate) Treatment for Post-menopausal Osteoporosis.	Completed	NCT00545480	Phase 4	ibandronate [Bonviva/Boniva]
23	A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy in Women With Post-Menopausal Osteoporosis or Osteopenia Transitioned From Once-Weekly Alendronate or Risendronate	Completed	NCT02604836	Phase 4	Ibandronate
24	An Open-Label, Multi-Center Study to Determine Level of Adherence to Monthly Oral or Every Three Month Intravenous Ibandronate Treatment in Post-Menopausal Women With Osteoporosis or Osteopenia, Who Are GI Intolerant of Daily or Weekly Alendronate or Risendronate	Completed	NCT02598453	Phase 4	Ibandronate
25	A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study	Completed	NCT02598440	Phase 4	Alendronate;Ibandronate
26	A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Phase IV Study in Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Actonel(Rosedronate) is Administered 35mg Once a Week or 5mg	Completed	NCT00549965	Phase 4	Risedronate Sodium
27	A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Study pn Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Risedronate Sodium (Actonel) in Administered 35mg Once a Week or 5mg Once Daily	Completed	NCT00453492	Phase 4	risedronate sodium
28	A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 35-mg Risedronate Administered Once a Week in the Prevention of Osteoporosis in Postmenopausal Women	Completed	NCT00402441	Phase 4	Risedronate (HMR4003)
29	Investigation of the Effects of Bisphosphonate on the Gingival Crevicular Fluid Levels of Sclerostin and the DKK-1 in Individuals With Postmenopausal Osteoporosis With Periodontal Changes	Completed	NCT04149405	Phase 4	Bisphosphonate therapy
30	A Randomized Open-Label Study to Investigate the Impact of Bone Marker Feedback at 3 Months on Adherence to Monthly Oral Bonviva in Women With Post-Menopausal Osteoporosis Supported by a Patient Relationship Program	Completed	NCT00545363	Phase 4	Ibandronate
31	Multicenter and Prospective Study to Determine the Satisfaction With Actonel (Risedronate Sodium) 35mg Once a Week Using Biochemical Markers of Bone as a Control, in Postmenopausal Women With Osteoporosis	Completed	NCT00632216	Phase 4	Risedronate Sodium
32	ZEST II for Osteoporotic Fracture Prevention	Completed	NCT02589600	Phase 4	Zoledronic acid
33	A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women	Completed	NCT00729651	Phase 4	alendronate sodium (+) cholecalciferol;Comparator: Alendronate sodium (Fosamax)
34	Multi-centre, Randomized, Open Label Trial to Evaluate the Effects of Switching to Bazedoxifene in Comparison With Switching to Calcium and Vitamin D in Postmenopausal Women Previously Treated With Bisphosphonates	Completed	NCT02090400	Phase 4	Bazedoxifene;Calcium/Vit D
35	Open Label, Parallel Group, Multicenter Study of Two Intravenous (IV) Ibandronate Dose Regimens (2 mg Every 2 Months and 3 mg Every 3 Months) in Women With Postmenopausal Osteoporosis Who Completed Trial BM16550	Completed	NCT00551174	Phase 4	ibandronate [Bonviva/Boniva]
36	Bone Marker Changes In One Month Treatment With TERIPARATIDE (LY333334) Injections (rDNA Origin) in Men and Postmenopausal Women With Severe Osteoporosis	Completed	NCT00532545	Phase 4	Teriparatide
37	A Randomized, Open Label Study Evaluating the Effect on Renal Function of Intravenous Bonviva Given by Injection or Infusion, Compared With Oral Alendronate, in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.	Completed	NCT00503113	Phase 4	ibandronate [Bonviva/Boniva];Alendronate
38	Pearlium®/Effecti-Cal®, a Novel Formulation of Calcium, Vitamin D and Minerals for Prevention of Postmenopausal Bone Loss	Completed	NCT04609189	Phase 4	Pearlium/EffectiCal;Calcium carbonate/vitamin D3
39	A Study of Prevention and Treatment of Postmenopausal Osteoporosis in Chinese Women	Completed	NCT00860964	Phase 4	Placebo;estradiol valerate
40	Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures	Completed	NCT01709110	Phase 4	Teriparatide;Risedronate;Placebo;Calcium;Vitamin D
41	A Randomised, Open Label Study to Investigate the Impact of Bone Marker Feedback at 2 Months on Adherence to Monthly Oral Bonviva (Ibandronate) in Women With Post-menopausal Osteoporosis.	Completed	NCT00545909	Phase 4	ibandronate [Bonviva/Boniva]
42	Impact of NTx Point of Care (POC) Device on Patient Satisfication With Actonel 35mg Once a Seek Treatment a Multicenter Prospective Open Label Randomized Controlled Community Practice-based Study	Completed	NCT00549068	Phase 4	Risedronate Sodium (Actonel)
43	An Open-label, Clinical Observation Extension Study to Assess Continuing Safety and Adherence in Patients With Postmenopausal Osteoporosis Receiving Monthly Oral Bonviva	Completed	NCT00545090	Phase 4	ibandronate [Bonviva/Boniva]
44	A Randomized, Double-blind Study to Evaluate the Effect of Once Monthly Bonviva on Lumbar Bone Mineral Density in the Prevention of Glucocorticoid-induced Osteoporosis in Post-menopausal Women	Completed	NCT00545051	Phase 4	Placebo;ibandronate
45	Long-Term Effects of Raloxifene Treatment on Bone Quality: A Cross-Sectional Study of Postmenopausal Women With Osteoporosis Previously Enrolled in the Continuing Outcomes Relevant to Evista Study	Completed	NCT00532428	Phase 4	Raloxifene;Placebo
46	A Study of Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene HCl or Placebo	Completed	NCT00532246	Phase 4	raloxifene;Placebo
47	An Open-label, Multi-centre, Randomized Study to Investigate Patient Preference on Dosing in the Once-monthly Ibandronate and the Once-weekly Risedronate in Korean Women With Postmenopausal Osteoporosis. A Six-month, Two-sequence, and Two Period Crossover Study	Completed	NCT00405392	Phase 4	Ibandronate (SB743830HD)
48	Double-blind, Partially Randomized, Parallel Group, Multicenter Study to Assess the Efficacy and Safety of 100 mg and 150 mg Monthly Oral Ibandronate in Women With Postmenopausal Osteoporosis Having Completed the Phase III Oral Ibandronate Trial BM16549	Completed	NCT00081653	Phase 4	ibandronate [Bonviva/Boniva]
49	Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis	Completed	NCT00035256	Phase 4	teriparatide;raloxifene HCl;placebo
50	Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy	Completed	NCT00927186	Phase 4	Teriparatide;Zoledronic Acid

Search NIH Clinical Center for Bone Mineral Density Quantitative Trait Locus 15

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Cholecalciferol

Fluorides

Medium chain triglycerides

MEDRONATE DISODIUM

SODIUM FLUORIDE PWDR

Sources

Genetic Tests for Bone Mineral Density Quantitative Trait Locus 15

Sources

Anatomical Context for Bone Mineral Density Quantitative Trait Locus 15

Organs/tissues related to Bone Mineral Density Quantitative Trait Locus 15:

MalaCards : Bone, Bone Marrow, Spinal Cord, Breast, Prostate, Kidney, Liver

Sources

Publications for Bone Mineral Density Quantitative Trait Locus 15

Articles related to Bone Mineral Density Quantitative Trait Locus 15:

(show top 50) (show all 32486)

#	Title	Authors	PMID	Year
1	A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. ⁶² ⁵⁷ ⁵	Li H...Luo XH	19920351	2009
2	Association of genetic variation of the RIL gene, encoding a PDZ-LIM domain protein and localized in 5q31.1, with low bone mineral density in adult Japanese women. ⁵	Omasu F...Emi M	12908099	2003
3	Calcitonin receptor polymorphism is associated with a decreased fracture risk in post-menopausal women. ⁵	Taboulet J...de Vernejoul MC	9817931	1998
4	Allelic variants of human calcitonin receptor: distribution and association with bone mass in postmenopausal Italian women. ⁵	Masi L...Brandi ML	9571205	1998
5	Allelic variants of human calcitonin receptor in the Japanese population. ⁵	Nakamura M...Kakudo K	9003491	1997
6	Ambient air pollution, bone mineral density and osteoporosis: Results from a national population-based cohort study. ⁶²	Yang Y...Lin H	36244420	2023
7	Emerging Role of 18F-NaF PET/Computed Tomographic Imaging in Osteoporosis: A Potential Upgrade to the Osteoporosis Toolbox. ⁶²	Sheppard AJ...Saboury B	36442958	2023
8	A biomimetic and bioactive scaffold with intelligently pulsatile teriparatide delivery for local and systemic osteoporosis regeneration. ⁶²	Che L...Song D	35441117	2023
9	Dietary interventions for better management of osteoporosis: An overview. ⁶²	Guo D...Hou T	34251926	2023
10	Equol exerts a protective effect on postmenopausal osteoporosis by upregulating OPG/RANKL pathway. ⁶²	Ni X...Wang J	36288653	2023
11	Osteoporosis and sarcopenia are associated with each other and reduced IGF1 levels are a risk for both diseases in the very old elderly. ⁶²	Hata R...Miyamoto T	36182103	2023
12	Er-Xian decoction attenuates ovariectomy-induced osteoporosis by modulating fatty acid metabolism and IGF1/PI3K/AKT signaling pathway. ⁶²	Ma Y...Zhang Z	36252878	2023
13	Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan. ⁶²	Iki M...Ogawa S	36347433	2023
14	Patient experience of telemedicine for osteoporosis care during the COVID-19 pandemic. ⁶²	Jones AR...Vincent AJ	34914125	2023
15	The Role of the Pharmacist in Patient Self-Advocacy for Osteoporosis Screening. ⁶²	McKeirnan KC...Undeberg MR	36461141	2022
16	Medical optimization of osteoporosis for adult spinal deformity surgery: a state-of-the-art evidence-based review of current pharmacotherapy. ⁶²	Zhang A...Daniels AH	36454531	2022
17	Asynchronous calibration of quantitative computed tomography bone mineral density assessment for opportunistic osteoporosis screening: phantom-based validation and parameter influence evaluation. ⁶²	Skornitzke S...Palm V	36456574	2022
18	The causal association of sarcopenia with osteoporosis and obesity: a Mendelian randomization analysis. ⁶²	Ran S...Liu BL	36469086	2022
19	Bone-Targeted delivery of senolytics to eliminate senescent cells increases bone formation in senile osteoporosis. ⁶²	Xing X...Tian W	36470392	2022
20	High prevalence and risk factors for osteoporosis in 1839 patients with systemic sclerosis: a systematic review and meta-analysis. ⁶²	Tu X...Wang J	36474110	2022
21	Prebiotics improve osteoporosis indicators in a preclinical model: systematic review with meta-analysis. ⁶²	Artoni de Carvalho JA...Bremer-Neto H	36474436	2022
22	Abaloparatide Improves Rotator Cuff Healing Via Anabolic Effects on Bone Remodeling in a Chronic Rotator Cuff Tear Model of Rat With Osteoporosis: A Comparison With Denosumab: Response. ⁶²	Xu J...Zhao J	36468703	2022
23	Isoorientin ameliorates osteoporosis and oxidative stress in postmenopausal rats. ⁶²	Cao Z...Zhao Z	36382865	2022
24	Conversion of osteoporotic vertebral fracture severity score to osteoporosis T-score equivalent status: a framework and a comparative study of Hong Kong Chinese and Rome Caucasian older women. ⁶²	Wang YXJ...Diacinti D	36462068	2022
25	The prevalence and treatment of osteoporosis in patients undergoing total hip arthroplasty and the levels of biochemical markers of bone turnover. ⁶²	Watanabe N...Okawa A	36464500	2022
26	AKT/GSK3β/NFATc1 and ROS signal axes are involved in AZD1390-mediated inhibitory effects on osteoclast and OVX-induced osteoporosis. ⁶²	Yang S...Liu Q	36327872	2022
27	Intervention thresholds and diagnostic thresholds in the management of osteoporosis. ⁶²	Kanis JA...Reginster JY	36344804	2022
28	A hypoxia-driven occurrence of chronic kidney disease and osteoporosis in COPD individuals: New insights into environmental cadmium exposure. ⁶²	Cirovic A...Landry GM	36265524	2022
29	SDH5 down-regulation mitigates the damage of osteoporosis via inhibiting the MyD88/NF-κB signaling pathway. ⁶²	Wu H...Liao Y	36326104	2022
30	Teff Grain-Based Functional Food for Prevention of Osteoporosis: Sensory Evaluation and Molecular Docking Approach. ⁶²	Asfha D...Vuppu S	36094586	2022
31	Effectiveness of Pharmacological Interventions for Treatment of Osteoporosis in Patients With CKD 3-5D: No Clear Choices. ⁶²	Khairallah P...Nickolas TL	36328907	2022
32	Corrigendum to "MicroRNA-874 targeting SUFU involves in osteoblast proliferation and differentiation in osteoporosis rats through the Hedgehog signaling pathway" [Biochem. Biophys. Res. Commun. 506(1) (2018) 194-203]. ⁶²	Lin JC...Zhang XR	36336525	2022
33	The prevalence of patients treated for osteoporosis in Greenland is low compared to Denmark. ⁶²	Sten KA...Albertsen N	35603589	2022
34	Romosozumab successfully regulated progressive osteoporosis in a patient with autosomal dominant polycystic kidney disease undergoing hemodialysis. ⁶²	Suzuki T...Honda H	35980440	2022
35	Advances in Diagnosis and Management of Childhood Osteoporosis ⁶²	Lim DBN...DaviesDavies JH	35984229	2022
36	Feasibility of assessing male osteoporosis using MRI IDEAL-IQ sequence of proximal femur in prostate cancer patients. ⁶²	Watanabe D...Mizushima A	35997228	2022
37	Dual-energy X-ray absorptiometry (DXA) to measure bone mineral density (BMD) for diagnosis of osteoporosis - experimental data from artificial vertebrae confirms significant dependence on bone size. ⁶²	Golding PH	35937936	2022
38	Two-year risedronate treatment for osteoporosis in patients with esophageal varices: a non-randomized clinical trial. ⁶²	Santos LAA...Romeiro FG	35767173	2022
39	Positive programming of the GC-IGF1 axis mediates adult osteoporosis susceptibility in male offspring rats induced by prenatal dexamethasone exposure. ⁶²	Shangguan Y...Chen L	36174767	2022
40	Pterostilbene-isothiocyanate impedes RANK/TRAF6 interaction to inhibit osteoclastogenesis, promoting osteogenesis in vitro and alleviating glucocorticoid induced osteoporosis in rats. ⁶²	Kumar V...Roy P	36209841	2022
41	Kefir peptides ameliorate osteoporosis in AKR1A1 knockout mice with vitamin C deficiency by promoting osteoblastogenesis and inhibiting osteoclastogenesis. ⁶²	Chang GR...Chen CM	36252352	2022
42	Single-cell RNA sequencing analysis dissected the osteo-immunology microenvironment and revealed key regulators in osteoporosis. ⁶²	Wang Y...Zhao F	36257255	2022
43	Comparison of postoperative outcomes in patients with and without osteoporosis undergoing single-level anterior cervical discectomy and fusion. ⁶²	Kammien AJ...Varthi A	36299450	2022
44	Effectiveness of Pharmacological Interventions Versus Placebo or No Treatment for Osteoporosis in Patients With CKD Stages 3-5D: Editorial Summary of a Cochrane Review. ⁶²	Hara T...Matsubara Y	36328908	2022
45	A comparison of different exercise intensities for improving bone mineral density in postmenopausal women with osteoporosis: A systematic review and meta-analysis. ⁶²	Kitagawa T...Yamamoto S	36310762	2022
46	The miRNA-144-5p/IRS1/AKT axis regulates the migration, proliferation, and mineralization of osteoblasts: A mechanism of bone repair in diabetic osteoporosis. ⁶²	Miao M...Shou D	36168858	2022
47	Response letter to "sarcopenia, osteoporosis and fractures: what we see". ⁶²	Harris RJ...Cauley JA	36469084	2022
48	Sarcopenia, osteoporosis, and fractures: what we see mainly depends on how we look? ⁶²	Kara M...Ozcakar L	36469085	2022
49	[Retracted] miR‑29b enhances the proliferation and migration of bone marrow mesenchymal stem cells in rats with castration‑induced osteoporosis through the PI3K/AKT and TGF‑β/Smad signaling pathways. ⁶²	Wang Y...Niu N	36382095	2022
50	[Osteoporosis: diagnostics and treatment]. ⁶²	Stumpf U...Bocker W	36445487	2022

Sources

Genes for Bone Mineral Density Quantitative Trait Locus 15

Genes related to Bone Mineral Density Quantitative Trait Locus 15 (1 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MIR2861	MicroRNA 2861	RNA Gene	550	Molecular basis known ⁵⁷ Typically genetic variations that lead to apparently abnormal laboratory test values ⁵⁷
2	CALCR	Calcitonin Receptor	Protein Coding	25	Risk factor ⁵	9003491 9571205 9817931
3	PDLIM4	PDZ And LIM Domain 4	Protein Coding	25	Risk factor ⁵	12908099
4	TRPV6	Transient Receptor Potential Cation Channel Subfamily V Member 6	Protein Coding	25	Likely pathogenic ⁵

Sources

Variations for Bone Mineral Density Quantitative Trait Locus 15

ClinVar genetic disease variations for Bone Mineral Density Quantitative Trait Locus 15:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	LOC113839511, MIR2861	NR_036055.1(MIR2861):n.33C>G	SNV	Association	106	rs794728003	GRCh37: 9:130548229-130548229 GRCh38: 9:127785950-127785950
2	PDLIM4	NC_000005.10:g.132251371C>T	SNV	Risk Factor	6348		GRCh37: 5:131587064-131587064 GRCh38: 5:132251371-132251371
3	CALCR	NM_001742.4(CALCR):c.1340T>C (p.Leu447Pro)	SNV	Risk Factor	17636	rs1801197	GRCh37: 7:93055753-93055753 GRCh38: 7:93426441-93426441
4	TRPV6	NM_018646.6(TRPV6):c.1978G>C (p.Gly660Arg)	SNV	Likely Pathogenic	818220	rs780306040	GRCh37: 7:142570162-142570162 GRCh38: 7:142872409-142872409